JP2019536786A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019536786A5 JP2019536786A5 JP2019528885A JP2019528885A JP2019536786A5 JP 2019536786 A5 JP2019536786 A5 JP 2019536786A5 JP 2019528885 A JP2019528885 A JP 2019528885A JP 2019528885 A JP2019528885 A JP 2019528885A JP 2019536786 A5 JP2019536786 A5 JP 2019536786A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- modified
- steroid
- pharmaceutical composition
- amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662428474P | 2016-11-30 | 2016-11-30 | |
| US62/428,474 | 2016-11-30 | ||
| PCT/US2017/064060 WO2018102606A1 (en) | 2016-11-30 | 2017-11-30 | Steroid administration and immunotherapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019536786A JP2019536786A (ja) | 2019-12-19 |
| JP2019536786A5 true JP2019536786A5 (enExample) | 2021-01-14 |
Family
ID=62241962
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019528885A Pending JP2019536786A (ja) | 2016-11-30 | 2017-11-30 | ステロイドの投与および免疫療法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20190351019A1 (enExample) |
| EP (1) | EP3548047A4 (enExample) |
| JP (1) | JP2019536786A (enExample) |
| KR (1) | KR20190090390A (enExample) |
| CN (1) | CN110234327A (enExample) |
| AU (1) | AU2017368248A1 (enExample) |
| CA (1) | CA3044261A1 (enExample) |
| WO (1) | WO2018102606A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2954311T3 (es) * | 2017-04-01 | 2023-11-21 | Avm Biotechnology Llc | Reemplazo de un preacondicionamiento citotóxico antes de una inmunoterapia celular |
| EP3820484A4 (en) * | 2018-07-10 | 2022-05-04 | Precigen, Inc. | ROR-1 SPECIFIC CHIMERA ANTIGEN RECEPTORS AND USES THEREOF |
| US12103946B2 (en) | 2018-10-08 | 2024-10-01 | New York University | Steroid compounds as Treg modulators and uses thereof |
| SE544015C2 (en) * | 2019-06-18 | 2021-11-02 | Tx Medic Ab | Allogenic car-t cell therapy |
| CN113616660A (zh) * | 2020-05-07 | 2021-11-09 | 深圳埃格林医药有限公司 | 孕激素制剂及其用途 |
| WO2022016150A1 (en) * | 2020-07-17 | 2022-01-20 | Ross Peter M | Methods for the treatment of cytokine release syndromes |
| WO2022109611A1 (en) | 2020-11-20 | 2022-05-27 | Simcere Innovation, Inc. | Armed dual car-t compositions and methods for cancer immunotherapy |
| JP2022091709A (ja) * | 2020-12-09 | 2022-06-21 | 株式会社ゲノム創薬研究所 | サイトカインストーム治療・予防剤のスクリーニング方法及びサイトカインストーム治療・予防剤 |
| US11969434B1 (en) | 2022-08-29 | 2024-04-30 | Lipocine Inc. | Oral allopregnanolone compositions and methods of use |
| US12186327B2 (en) | 2022-08-29 | 2025-01-07 | Lipocine Inc. | Oral allopregnanolone compositions and methods of use |
| WO2026092543A1 (en) * | 2024-10-29 | 2026-05-07 | Shenzhen Genocury Biotech Co., Ltd | Methods and compositions of prophylactic therapy for preventing crs |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1684758A4 (en) * | 2003-11-06 | 2009-02-18 | Celgene Corp | METHODS AND COMPOSITIONS USING THALIDOMIDE FOR THE TREATMENT AND MANAGEMENT OF CANCERS AND OTHER DISEASES |
| WO2011053322A1 (en) * | 2009-10-30 | 2011-05-05 | University Of Arkansas For Medical Science | Use of autologous effector cells and antibodies for treatment of multiple myeloma |
| US20150290244A1 (en) * | 2012-07-13 | 2015-10-15 | The Trustees Of The University Of Pennsylvania | Use of cart19 to deplete normal b cells to induce tolerance |
| AU2015243849B2 (en) * | 2014-04-10 | 2020-12-17 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Transgene genetic tags and methods of use |
| MY181834A (en) * | 2014-07-21 | 2021-01-08 | Novartis Ag | Treatment of cancer using humanized anti-bcma chimeric antigen receptor |
| AU2016249005B2 (en) * | 2015-04-17 | 2022-06-16 | Novartis Ag | Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells |
-
2017
- 2017-11-30 EP EP17875779.5A patent/EP3548047A4/en not_active Withdrawn
- 2017-11-30 CN CN201780085063.3A patent/CN110234327A/zh active Pending
- 2017-11-30 KR KR1020197018023A patent/KR20190090390A/ko not_active Ceased
- 2017-11-30 AU AU2017368248A patent/AU2017368248A1/en not_active Abandoned
- 2017-11-30 JP JP2019528885A patent/JP2019536786A/ja active Pending
- 2017-11-30 CA CA3044261A patent/CA3044261A1/en active Pending
- 2017-11-30 WO PCT/US2017/064060 patent/WO2018102606A1/en not_active Ceased
-
2019
- 2019-05-24 US US16/421,763 patent/US20190351019A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Marabelle et al. | Intratumoral immunization: a new paradigm for cancer therapy | |
| Page et al. | Two may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancer | |
| Gill et al. | Chimeric antigen receptor T cell therapy: 25 years in the making | |
| Sagiv-Barfi et al. | Eradication of spontaneous malignancy by local immunotherapy | |
| Fournier et al. | Trial watch: adoptively transferred cells for anticancer immunotherapy | |
| JP2017531687A5 (enExample) | ||
| Kazemi et al. | Immunotherapeutic approaches for cancer therapy: an updated review | |
| PH12021552300A1 (en) | EGFR x CD28 MULTISPECIFIC ANTIBODIES | |
| JP6877147B2 (ja) | 放射線療法と併用されるｐｄ−１およびｐｄ−ｌ１に対する拮抗薬を用いたがんの治療法 | |
| HRP20211948T1 (hr) | Djelatna sredstva koja se vežu na tigit i njihove uporabe | |
| JP2015509716A5 (enExample) | ||
| HRP20221191T1 (hr) | Humana antitijela koja vezuju limfocitni aktivacijski gen-3 (lag-3) i njihove primjene | |
| JP2017537892A5 (enExample) | ||
| Fantini et al. | Potentiation of natural killer cells to overcome cancer resistance to NK cell-based therapy and to enhance antibody-based immunotherapy | |
| JP2018522567A5 (enExample) | ||
| RU2017105425A (ru) | Комбинации антитела против cd94/nkg2a и/или cd94/nkg2b и вакцины | |
| JP2015509717A5 (enExample) | ||
| JP2010522772A5 (enExample) | ||
| Chmielewski et al. | T cells redirected by a CD3ζ chimeric antigen receptor can establish self-antigen-specific tumour protection in the long term | |
| Pierini et al. | Trial watch: DNA-based vaccines for oncological indications | |
| Qian et al. | Update for advance CAR-T therapy in solid tumors, clinical application in peritoneal carcinomatosis from colorectal cancer and future prospects | |
| JP2021535149A5 (enExample) | ||
| Pieper et al. | Radiation augments the local anti-tumor effect of in situ vaccine with CpG-oligodeoxynucleotides and anti-OX40 in immunologically cold tumor models | |
| JP2018518465A5 (enExample) | ||
| CN111065410A (zh) | 用于改善过继细胞疗法的方法 |